A novel series of N-(1-phenyl-2-benzimidazolyl)-N′-phenylurea derivatives were prepared as ACAT inhibitors. These compounds showed potent ACAT inhibitory activity in vitro (liver microsomes from cholesterol-fed rabbits) and hypocholesterolemic activity in vivo (cholesterol-fed golden hamsters).